Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-5

Add to that:



"rapidly advancing toward having four Phase 1 clinical trials underway backed by seven novel assets in development overall, setting the platform for a busy period of news flow for our sharehodlers and investors"
- Paul Hopper, Executive Chairman, September 2022


We now (January 2023) have two Phase 1 clinical trials underway:

CHM 1101 (CLTX CAR T): https://clinicaltrials.gov/ct2/show/NCT04214392
Status: Dosing in 3rd (of 4) cohort complete, and "once the final evaluable patient of this third cohort successfully completes the 28 DLT period, the study will be able to advance to recruitment of patients at the furth and final dose level" - which happens to be today

CHM 0201 CORE NK) Vactosertib combo: https://clinicaltrials.gov/ct2/show/NCT05400122
Status: First patient dosed
Note: "The Phase 1b trial is currently funded without financial support from Chimeric Therapeutics"


Next:

CHM 1101 (CLTX CAR T): https://clinicaltrials.gov/ct2/show/NCT05627323
Status: Not yet recruiting
Note: Two dose levels investigated, with both dose levels proceeding in parallel

CHM 2101 (CDH17 CAR T)
Status: waiting for FDA IND clearance
"Our team has been intensely dedicated in 2022 to completing all of the work necessary to move CHM 2101 into a phase 1 clinical trial as soon as possible."
- Jennifer Chow, CEO & MD, December 2022


More information can be found on the website, "Our Pipeline."


Market Capital: A$36 million